# Mary F Paine

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 92 papers | 5,075 citations | 36 h-index | 70 g-index |
| 105 ext. papers | 5,557 ext. citations | 4.7 avg, IF | 5.38 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 92 | Sex-specific pharmacological differences **2022**, 405-424 | | |
| 91 | Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. *Clinical and Translational Science*, **2021**, | 4.9 | 1 |
| 90 | Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, | 5.9 | 12 |
| 89 | Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 55-64 | 6.1 | 15 |
| 88 | Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1342-1352 | 6.1 | 4 |
| 87 | Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 376, 64-73 | 4.7 | 8 |
| 86 | Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. *Phytotherapy Research*, **2021**, 35, 3286-3297 | 6.7 | 3 |
| 85 | Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. *Pharmacological Reviews*, **2021**, 73, 847-859 | 22.5 | 2 |
| 84 | "Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents. *Regulatory Toxicology and Pharmacology*, **2020**, 113, 104642 | 3.4 | 17 |
| 83 | Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects. *Drug Metabolism and Disposition*, **2020**, 48, 1018-1027 | 4 | 4 |
| 82 | A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. *Drug Metabolism and Disposition*, **2020**, 48, 1104-1112 | 4 | 1 |
| 81 | Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. *Drug Metabolism and Disposition*, **2020**, 48, 1008-1017 | 4 | 19 |
| 80 | United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. *Toxicology Reports*, **2020**, 7, 386-402 | 4.8 | 55 |
| 79 | Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. *Natural Product Reports*, **2019**, 36, 1196-1221 | 15.1 | 49 |
| 78 | A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. *Pharmacology & Therapeutics*, **2019**, 201, 25-38 | 13.9 | 36 |
| 77 | Indinavir Increases Midazolam -Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. *Drug Metabolism and Disposition*, **2019**, 47, 724-731 | 4 | 0 |
| 76 | Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. *Toxicon*, **2019**, 162, 1-8 | 2.8 | 7 |

| | | | |
|---|---|---|---|
| 75 | A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 371, 385-393 | 4.7 | 5 |
| 74 | Heterotropic Cooperativity for CYP3A4-Mediated 1?-Hydroxylation of Midazolam by Berberine: An In Silico Modeling and Simulation Study. *FASEB Journal*, **2019**, 33, 508.5 | 0.9 | |
| 73 | Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis. *Clinical and Translational Science*, **2019**, 12, 39-46 | 4.9 | 20 |
| 72 | Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea ( Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. *Drug Metabolism and Disposition*, **2018**, 46, 552-560 | 4 | 17 |
| 71 | Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. *Drug Metabolism and Disposition*, **2018**, 46, 1041-1045 | 4 | 15 |
| 70 | Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. *Drug Metabolism and Disposition*, **2018**, 46, 1046-1052 | 4 | 14 |
| 69 | Follow that botanical: Challenges and recommendations for assessing absorption, distribution, metabolism and excretion of botanical dietary supplements. *Food and Chemical Toxicology*, **2018**, 121, 194-202 | 4.7 | 11 |
| 68 | ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. *Clinical Pharmacology and Therapeutics*, **2018** , 104, 781-784 | 6.1 | 14 |
| 67 | Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study. *Journal of Natural Products*, **2017**, 80, 1457-1466 | 4.9 | 38 |
| 66 | Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 251-259 | 1.7 | 16 |
| 65 | Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. *Drug Metabolism and Disposition*, **2015**, 43, 490-509 | 4 | 91 |
| 64 | Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. *Drug Metabolism and Disposition*, **2015**, 43, 1353-9 | 4 | 17 |
| 63 | Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003409 | 4.8 | 15 |
| 62 | Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 352, 462-70 | 4.7 | 37 |
| 61 | Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance. *Drug Metabolism and Disposition*, **2015**, 43, 34-41 | 4 | 22 |
| 60 | Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers. *CPT: Pharmacometrics and Systems Pharmacology*, **2015**, 4, 701-10 | 4.5 | 17 |
| 59 | Drug Metabolism, Transport, and Pharmacogenomics **2015**, 626-638 | | |
| 58 | Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides. *Drug Metabolism and Disposition*, **2015**, 43, 1734-43 | 4 | 5 |

| | | | |
|---|---|---|---|
| 57 | Understanding the transport properties of metabolites: case studies and considerations for drug development. *Drug Metabolism and Disposition*, **2014**, 42, 650-64 | 4 | 42 |
| 56 | Herb-drug interactions: challenges and opportunities for improved predictions. *Drug Metabolism and Disposition*, **2014**, 42, 301-17 | 4 | 113 |
| 55 | Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity. *Journal of Pharmaceutical and Biomedical Analysis*, **2014**, 98, 260-5 | 3.5 | 9 |
| 54 | Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. *Drug Metabolism and Disposition*, **2014**, 42, 1675-83 | 4 | 39 |
| 53 | Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 351, 576-84 | 4.7 | 9 |
| 52 | Characterizing the abuse potential of loperamide via physiologically-based pharmacokinetic/pharmacodynamic modeling and simulation (1053.6). *FASEB Journal*, **2014**, 28, 1053.6 | 0.9 | |
| 51 | Enhanced bioactivity of silybin B methylation products. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 742-7 | 3.4 | 23 |
| 50 | A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. *Drug Metabolism and Disposition*, **2013**, 41, 1662-70 | 4 | 30 |
| 49 | Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 3919-26 | 3.4 | 19 |
| 48 | Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2230 | 4.8 | 14 |
| 47 | Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid Chromatography. *Phytochemical Analysis*, **2013**, 24, 654-60 | 3.4 | 19 |
| 46 | A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect". *Journal of Clinical Pharmacology*, **2013**, 53, 982-90 | 2.9 | 7 |
| 45 | Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug. *Drug Metabolism and Disposition*, **2013**, 41, 518-28 | 4 | 6 |
| 44 | Assessing drug interaction risk of the grapefruit juice component and dietary supplement 6?,7?-dihydroxybergamottin via physiologically-based pharmacokinetic modeling and simulation. *FASEB Journal*, **2013**, 27, 1103.4 | 0.9 | |
| 43 | Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. *Pharmacology & Therapeutics*, **2012**, 136, 186-201 | 13.9 | 82 |
| 42 | Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1734 | 4.8 | 30 |
| 41 | A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. *Toxicological Sciences*, **2012**, 130, 416-26 | 4.4 | 47 |
| 40 | A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. *Drug Metabolism and Disposition*, **2012**, 40, 6-17 | 4 | 19 |

| | | | |
|---|---|---|---|
| 39 | Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. *Drug Metabolism and Disposition*, **2012**, 40, 2136-42 | 4 | 16 |
| 38 | Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. *Planta Medica*, **2011**, 77, 265-70 | 3.1 | 37 |
| 37 | Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 337, 503-12 | 4.7 | 22 |
| 36 | Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 334, 410-8 | 4.7 | 23 |
| 35 | Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 332, 1081-7 | 4.7 | 67 |
| 34 | Influence of dietary substances on intestinal drug metabolism and transport. *Current Drug Metabolism*, **2010**, 11, 778-92 | 3.5 | 30 |
| 33 | Diamidines for human African trypanosomiasis. *Current Opinion in Investigational Drugs*, **2010**, 11, 876-83 | | 59 |
| 32 | Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. *Drug Metabolism and Disposition*, **2009**, 37, 514-22 | 4 | 35 |
| 31 | The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. *Drug Metabolism and Disposition*, **2008**, 36, 146-54 | 4 | 39 |
| 30 | The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. *Drug Metabolism and Disposition*, **2008**, 36, 1465-9 | 4 | 25 |
| 29 | Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. *American Journal of Clinical Nutrition*, **2008**, 87, 863-71 | 7 | 46 |
| 28 | A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. *Proteomics*, **2008**, 8, 4186-96 | 4.8 | 37 |
| 27 | Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. *Drug Metabolism and Disposition*, **2007**, 35, 2067-75 | 4 | 46 |
| 26 | Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 67-80 | 5.5 | 49 |
| 25 | CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. *Drug Metabolism and Disposition*, **2006**, 34, 1985-94 | 4 | 75 |
| 24 | The human intestinal cytochrome P450 "pie". *Drug Metabolism and Disposition*, **2006**, 34, 880-6 | 4 | 666 |
| 23 | A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. *American Journal of Clinical Nutrition*, **2006**, 83, 1097-105 | 7 | 122 |
| 22 | Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. *Clinical Pharmacology and Therapeutics*, **2005**, 78, 605-18 | 6.1 | 77 |

| | | | |
|---|---|---|---|
| 21 | A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. *Digestive Diseases and Sciences*, **2005**, 50, 2312-5 | 4 | 19 |
| 20 | Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?. *Drug Metabolism and Disposition*, **2005**, 33, 426-33 | 4 | 94 |
| 19 | Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1151-60 | 4.7 | 76 |
| 18 | Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. *Drug Metabolism and Disposition*, **2004**, 32, 1146-53 | 4 | 78 |
| 17 | 6',7'-Dihydroxybergamottin contributes to the grapefruit juice effect. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 569-79 | 6.1 | 51 |
| 16 | Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 308, 941-8 | 4.7 | 50 |
| 15 | New insights into drug absorption: studies with sirolimus. *Therapeutic Drug Monitoring*, **2004**, 26, 463-7 | 3.2 | 21 |
| 14 | P-glycoprotein increases from proximal to distal regions of human small intestine. *Pharmaceutical Research*, **2003**, 20, 1595-9 | 4.5 | 220 |
| 13 | Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?. *British Journal of Clinical Pharmacology*, **2002**, 54, 643-51 | 3.8 | 13 |
| 12 | Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. *Clinical Pharmacology and Therapeutics*, **2002**, 72, 524-35 | 6.1 | 37 |
| 11 | Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 301, 174-86 | 4.7 | 42 |
| 10 | The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. *Drug Metabolism Reviews*, **2001**, 33, 273-97 | 7 | 327 |
| 9 | Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. *Clinical Pharmacology and Therapeutics*, **2001**, 69, 14-23 | 6.1 | 135 |
| 8 | Effect of grapefruit juice on the disposition of omeprazole. *British Journal of Clinical Pharmacology*, **2001**, 52, 213-217 | 3.8 | 4 |
| 7 | Can oral midazolam predict oral cyclosporine disposition?. *European Journal of Pharmaceutical Sciences*, **2000**, 12, 51-62 | 5.1 | 15 |
| 6 | Immunochemical identification of UGT isoforms in human small bowel and in caco-2 cell monolayers. *Biochemical and Biophysical Research Communications*, **2000**, 273, 1053-7 | 3.4 | 30 |
| 5 | Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. *Pharmaceutical Research*, **1999**, 16, 1199-205 | 4.5 | 65 |
| 4 | Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. *Molecular Pharmacology*, **1997**, 51, 741-54 | 4.3 | 287 |

| | | | |
|---|---|---|---|
| 3 | First-pass metabolism of midazolam by the human intestine. *Clinical Pharmacology and Therapeutics* , **1996**, 60, 14-24 | 6.1 | 394 |
| 2 | Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. *Clinical Pharmacology and Therapeutics*, **1996**, 59, 491-502 | 6.1 | 504 |
| 1 | Clinical relevance of hepatic and renal P-gp/ BCRP inhibition of drugs: An International Transporter Consortium perspective. *Clinical Pharmacology and Therapeutics*, | 6.1 | 1 |